Novavax (NVAX) Research & Development (2010 - 2026)
Novavax (NVAX) posted quarterly Research & Development of $95.5 million for Q1 2026, up 7.35% year-over-year from $88.9 million in Q1 2025, and up 25.83% quarter-over-quarter from $75.9 million in Q4 2025.
Novavax (NVAX) Research & Development (2010 - 2026) Analysis & Trends
Novavax's Research & Development history runs 17 years deep, the most recent figure standing at $95.5 million for Q1 2026.
- In Q1 2026, Research & Development rose 7.35% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $348.9 million (down 9.96% YoY), while the FY2025 annual figure was $342.3 million, down 12.49% from the prior year.
- Research & Development for Q1 2026 stood at $95.5 million, up from $75.9 million in the prior quarter.
- The five-year high for Research & Development was $383.5 million in Q1 2022, with the low at $75.9 million in Q4 2025.
- The 5-year median for Research & Development is $106.2 million (2023), against an average of $164.8 million.
- The sharpest annual moves came in 2022 and 2025: Research & Development slumped 73.22% in 2022, then increased 12.75% in 2025.
- Novavax's Research & Development stood at $257.8 million in 2022, then slumped by 36.13% to $164.7 million in 2023, then slumped by 36.62% to $104.4 million in 2024, then retreated by 27.31% to $75.9 million in 2025, then advanced by 25.83% to $95.5 million in 2026.
- Business Quant data shows NVAX's Research & Development at $95.5 million in Q1 2026, $75.9 million in Q4 2025, and $98.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | 70.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 70.69 Mn |
| Mar 31, 2026 | 95.47 Mn |
| Dec 31, 2025 | 75.88 Mn |
| Sep 30, 2025 | 98.27 Mn |
| Jun 30, 2025 | 79.23 Mn |
| Mar 31, 2025 | 88.94 Mn |
| Dec 31, 2024 | 104.38 Mn |
| Sep 30, 2024 | 87.16 Mn |
| Jun 30, 2024 | 106.95 Mn |
| Mar 31, 2024 | 92.68 Mn |
| Dec 31, 2023 | 164.70 Mn |
| Sep 30, 2023 | 106.23 Mn |
| Jun 30, 2023 | 219.48 Mn |
| Mar 31, 2023 | 247.10 Mn |
| Dec 31, 2022 | 257.85 Mn |
| Sep 30, 2022 | 304.30 Mn |
| Jun 30, 2022 | 289.65 Mn |
| Mar 31, 2022 | 383.48 Mn |
| Dec 31, 2021 | 962.96 Mn |
| Sep 30, 2021 | 408.20 Mn |